{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T14:05:32Z","timestamp":1784210732797,"version":"3.55.0"},"reference-count":152,"publisher":"Bioscientifica","issue":"7","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82573857"],"award-info":[{"award-number":["82573857"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100022963","name":"Key Research and Development Program of Zhejiang Province","doi-asserted-by":"crossref","award":["2024C03157"],"award-info":[{"award-number":["2024C03157"]}],"id":[{"id":"10.13039\/100022963","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The B7 family exerts complex and diverse immunomodulatory effects on the occurrence and development of thyroid diseases. The abnormal expression and polymorphisms of B7 family molecules in autoimmune thyroid diseases result in the disruption of immune tolerance, activation of autoreactive T cells, and thyroid tissue damage. The dysfunction of the B7 family is also closely related to the progression of thyroid cancer (TC) through remodeling the tumor microenvironment and mediating immune evasion. Of note, targeting the B7 family has become a promising strategy for TC treatment. In addition, B7 family signaling linking to immune cell subsets, tertiary lymphoid structure formation, and therapeutic response are also discussed. With the emerging findings of B7 family members in thyroid diseases, understanding the comprehensive roles and mechanisms of B7 molecules would facilitate the clinical translation of B7-based immunotherapy.<\/jats:p>","DOI":"10.1530\/erc-25-0435","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T13:20:46Z","timestamp":1782825646000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":0,"title":["The role of the B7 family in autoimmune thyroid diseases and thyroid cancer"],"prefix":"10.1530","volume":"33","author":[{"given":"Ruidan","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, Institute of Pharmacology, Zhejiang University of Technology 1 , ,","place":["Hangzhou, China"]},{"name":"Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People\u2019s Hospital (Affiliated People\u2019s Hospital), Hangzhou Medical College 2 , ,","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulu","family":"Che","sequence":"additional","affiliation":[{"name":"Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People\u2019s Hospital (Affiliated People\u2019s Hospital), Hangzhou Medical College 2 , ,","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Gong","sequence":"additional","affiliation":[{"name":"Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People\u2019s Hospital (Affiliated People\u2019s Hospital), Hangzhou Medical College 2 , ,","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People\u2019s Hospital (Affiliated People\u2019s Hospital), Hangzhou Medical College 2 , ,","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwen","family":"Fang","sequence":"additional","affiliation":[{"name":"Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People\u2019s Hospital (Affiliated People\u2019s Hospital), Hangzhou Medical College 2 , ,","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4054-6660","authenticated-orcid":true,"given":"Zongfu","family":"Pan","sequence":"additional","affiliation":[{"name":"Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People\u2019s Hospital (Affiliated People\u2019s Hospital), Hangzhou Medical College 2 , ,","place":["Hangzhou, China"]},{"name":"Zhejiang Key Laboratory of Precision Medicine Research on Head & Neck Cancer, Zhejiang Provincial People\u2019s Hospital 3 , ,","place":["Hangzhou, China"]},{"name":"Zhejiang Provincial Clinical Research Center for Head & Neck Cancer, Zhejiang Provincial People\u2019s Hospital 4 , ,","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"2026071609163920200_bib1","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrendo.2018.18","article-title":"Global epidemiology of hyperthyroidism and hypothyroidism","volume":"14","author":"Taylor","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"2026071609163920200_bib2","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/ijc.33588","article-title":"Cancer statistics for the year 2020: an overview","volume":"149","author":"Ferlay","year":"2021","journal-title":"Int J Cancer"},{"key":"2026071609163920200_bib3","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.8759","article-title":"Global burden of thyroid cancer from 1990 to 2017","volume":"3","author":"Deng","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2026071609163920200_bib4","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2026071609163920200_bib5","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1146\/annurev.immunol.23.021704.115611","article-title":"The B7 family revisited","volume":"23","author":"Greenwald","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"2026071609163920200_bib6","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1146\/annurev.immunol.021908.132706","article-title":"T cell activation","volume":"27","author":"Smith-Garvin","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"2026071609163920200_bib7","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nri727","article-title":"The B7-CD28 superfamily","volume":"2","author":"Sharpe","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"2026071609163920200_bib8","doi-asserted-by":"crossref","first-page":"10719","DOI":"10.3390\/ijms221910719","article-title":"The positive and negative immunoregulatory role of B7 family: promising novel targets in gastric cancer treatment","volume":"22","author":"Bolandi","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026071609163920200_bib9","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13045-022-01364-7","article-title":"Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy","volume":"15","author":"Zhao","year":"2022","journal-title":"J Hematol Oncol"},{"key":"2026071609163920200_bib10","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jaut.2015.07.009","article-title":"Immunogenetics of autoimmune thyroid diseases: a comprehensive review","volume":"64","author":"Lee","year":"2015","journal-title":"J Autoimmun"},{"key":"2026071609163920200_bib11","doi-asserted-by":"crossref","first-page":"e2970","DOI":"10.1210\/clinem\/dgaa309","article-title":"EV PD-L1 is correlated with clinical features and contributes to T cell suppression in pediatric thyroid cancer","volume":"105","author":"Wang","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2026071609163920200_bib12","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1172\/JCI25673","article-title":"VSIG4, a B7 family-related protein, is a negative regulator of T cell activation","volume":"116","author":"Vogt","year":"2006","journal-title":"J Clin Investig"},{"key":"2026071609163920200_bib13","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1038\/s41423-020-0494-8","article-title":"ERMAP is a B7 family-related molecule that negatively regulates T cell and macrophage responses","volume":"18","author":"Su","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"2026071609163920200_bib14","doi-asserted-by":"crossref","first-page":"400","DOI":"10.4049\/jimmunol.1800639","article-title":"Skint8, a novel B7 family-related molecule, negatively regulates T cell responses","volume":"203","author":"Lin","year":"2019","journal-title":"J Immunol"},{"key":"2026071609163920200_bib15","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/gb-2005-6-6-223","article-title":"The B7 family of immune-regulatory ligands","volume":"6","author":"Collins","year":"2005","journal-title":"Genome Biol"},{"key":"2026071609163920200_bib16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1074-7613(00)80158-2","article-title":"Structure and dimerization of a soluble form of B7-1","volume":"12","author":"Ikemizu","year":"2000","journal-title":"Immunity"},{"key":"2026071609163920200_bib17","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/intimm\/7.2.171","article-title":"Cloning the rat homolog of the CD28\/CTLA-4-ligand B7-1: structural and functional analysis","volume":"7","author":"Judge","year":"1995","journal-title":"Int Immunol"},{"key":"2026071609163920200_bib18","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.imlet.2005.11.019","article-title":"B7-1 and B7-2: similar costimulatory ligands with different biochemical, oligomeric and signaling properties","volume":"104","author":"Bhatia","year":"2006","journal-title":"Immunol Lett"},{"key":"2026071609163920200_bib19","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/35069118","article-title":"Crystal structure of the B7-1\/CTLA-4 complex that inhibits human immune responses","volume":"410","author":"Stamper","year":"2001","journal-title":"Nature"},{"key":"2026071609163920200_bib20","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1084\/jem.185.3.393","article-title":"CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics","volume":"185","author":"van der Merwe","year":"1997","journal-title":"J Exp Med"},{"key":"2026071609163920200_bib21","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1016\/j.str.2015.09.010","article-title":"Structure of the complex of human programmed death 1, PD-1, and its ligand PD-L1","volume":"23","author":"Zak","year":"2015","journal-title":"Structure"},{"key":"2026071609163920200_bib22","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1073\/pnas.0712278105","article-title":"The PD-1\/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors","volume":"105","author":"Lin","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026071609163920200_bib23","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12943-025-02330-w","article-title":"N-glycosylation of PD-L1 modulates the efficacy of immune checkpoint blockades targeting PD-L1 and PD-1","volume":"24","author":"Kaufman","year":"2025","journal-title":"Mol Cancer"},{"key":"2026071609163920200_bib24","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.3389\/fimmu.2020.02104","article-title":"ICOS(+) tregs: a functional subset of tregs in immune diseases","volume":"11","author":"Li","year":"2020","journal-title":"Front Immunol"},{"key":"2026071609163920200_bib25","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/14712598.2020.1693540","article-title":"Role of inducible Co-Stimulator (ICOS) in cancer immunotherapy","volume":"20","author":"Amatore","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"2026071609163920200_bib26","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.intimp.2016.05.020","article-title":"Could B7-H4 serve as a target to activate anti-cancer immunity?","volume":"38","author":"Wang","year":"2016","journal-title":"Int Immunopharmacol"},{"key":"2026071609163920200_bib27","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S1074-7613(03)00152-3","article-title":"B7-H4, a molecule of the B7 family, negatively regulates T cell immunity","volume":"18","author":"Sica","year":"2003","journal-title":"Immunity"},{"key":"2026071609163920200_bib28","doi-asserted-by":"crossref","first-page":"4254","DOI":"10.1038\/s41467-025-58552-5","article-title":"Palmitoylation prevents B7-H4 lysosomal degradation sustaining tumor immune evasion","volume":"16","author":"Yan","year":"2025","journal-title":"Nat Commun"},{"key":"2026071609163920200_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101653","article-title":"MALAT-1: immunomodulatory lncRNA hampering the innate and the adaptive immune arms in triple negative breast cancer","volume":"31","author":"Mekky","year":"2023","journal-title":"Transl Oncol"},{"key":"2026071609163920200_bib30","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s40478-021-01167-w","article-title":"The expression of B7-H3 isoforms in newly diagnosed glioblastoma and recurrence and their functional role","volume":"9","author":"Digregorio","year":"2021","journal-title":"Acta Neuropathol Commun"},{"key":"2026071609163920200_bib31","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12943-023-01751-9","article-title":"New frontiers in immune checkpoint B7-H3 (CD276) research and drug development","volume":"22","author":"Getu","year":"2023","journal-title":"Mol Cancer"},{"key":"2026071609163920200_bib32","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/1078-0432.CCR-20-2584","article-title":"B7-H3: an attractive target for antibody-based immunotherapy","volume":"27","author":"Kontos","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026071609163920200_bib33","doi-asserted-by":"crossref","first-page":"30018","DOI":"10.1074\/jbc.M115.679852","article-title":"Humanized affinity-matured monoclonal antibody 8H9 has potent antitumor activity and binds to FG loop of tumor antigen B7-H3","volume":"290","author":"Ahmed","year":"2015","journal-title":"J Biol Chem"},{"key":"2026071609163920200_bib34","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s42003-023-05736-8","article-title":"Dimerization of the 4Ig isoform of B7-H3 in tumor cells mediates enhanced proliferation and tumorigenic signaling","volume":"7","author":"Sutton","year":"2024","journal-title":"Commun Biol"},{"key":"2026071609163920200_bib35","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1084\/jem.20100619","article-title":"VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses","volume":"208","author":"Wang","year":"2011","journal-title":"J Exp Med"},{"key":"2026071609163920200_bib36","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41586-019-1674-5","article-title":"VISTA is an acidic pH-selective ligand for PSGL-1","volume":"574","author":"Johnston","year":"2019","journal-title":"Nature"},{"key":"2026071609163920200_bib37","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1158\/1078-0432.CCR-14-1495","article-title":"Expression, clinical significance, and receptor identification of the newest B7 family member HHLA2 protein","volume":"21","author":"Janakiram","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2026071609163920200_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114639","article-title":"HHLA2 immune-regulatory roles in cancer","volume":"162","author":"Mortezaee","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"2026071609163920200_bib39","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abf9792","article-title":"KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target","volume":"6","author":"Wei","year":"2021","journal-title":"Sci Immunol"},{"key":"2026071609163920200_bib40","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jare.2022.07.013","article-title":"KIR3DL3-HHLA2 and TMIGD2-HHLA2 pathways: the dual role of HHLA2 in immune responses and its potential therapeutic approach for cancer immunotherapy","volume":"47","author":"Li","year":"2023","journal-title":"J Adv Res"},{"key":"2026071609163920200_bib41","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature05263","article-title":"Structure of C3b in complex with CRIg gives insights into regulation of complement activation","volume":"444","author":"Wiesmann","year":"2006","journal-title":"Nature"},{"key":"2026071609163920200_bib42","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1097\/PAS.0000000000002284","article-title":"PD-L1 expression and its modulating factors in anaplastic thyroid carcinoma: a multi-institutional study","volume":"48","author":"Agarwal","year":"2024","journal-title":"Am J Surg Pathol"},{"key":"2026071609163920200_bib43","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s12022-024-09832-1","article-title":"Unravelling the reasons behind limited response to anti-PD therapy in ATC: a comprehensive evaluation of tumor-infiltrating immune cells and checkpoints","volume":"35","author":"Boruah","year":"2024","journal-title":"Endocr Pathol"},{"key":"2026071609163920200_bib44","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s12022-024-09822-3","article-title":"PD-L1 and B7-H3 are effective prognostic factors and potential therapeutic targets for high-risk thyroid cancer","volume":"35","author":"Zhu","year":"2024","journal-title":"Endocr Pathol"},{"key":"2026071609163920200_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.859013","article-title":"Immune checkpoint protein expression defines the prognosis of advanced thyroid carcinoma","volume":"13","author":"Luo","year":"2022","journal-title":"Front Endocrinol"},{"key":"2026071609163920200_bib46","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1093\/jjco\/hyac040","article-title":"High expression of HHLA2 predicts poor prognosis in medullary thyroid carcinoma","volume":"52","author":"Niu","year":"2022","journal-title":"Jpn J Clin Oncol"},{"key":"2026071609163920200_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2022.166591","article-title":"IL2RA(+)VSIG4(+) tumor-associated macrophage is a key subpopulation of the immunosuppressive microenvironment in anaplastic thyroid cancer","volume":"1869","author":"Pan","year":"2023","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"2026071609163920200_bib48","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1210\/er.2013-1055","article-title":"Breaking tolerance to thyroid antigens: changing concepts in thyroid autoimmunity","volume":"35","author":"McLachlan","year":"2014","journal-title":"Endocr Rev"},{"key":"2026071609163920200_bib49","doi-asserted-by":"crossref","first-page":"6883","DOI":"10.3390\/ijms25136883","article-title":"The role of the immune system in the course of Hashimoto\u2019s thyroiditis: the current state of knowledge","volume":"25","author":"Wro\u0144ska","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026071609163920200_bib50","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1365-2249.2006.03080.x","article-title":"Maturation of dendritic cells by necrotic thyrocytes facilitates induction of experimental autoimmune thyroiditis","volume":"144","author":"Li","year":"2006","journal-title":"Clin Exp Immunol"},{"key":"2026071609163920200_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.26502\/aimr.0232","article-title":"Immunopathogenesis, diagnosis, and treatment of Hashimoto\u2019s thyroiditis","volume":"9","author":"Delgadillo","year":"2026","journal-title":"Arch Intern Med Res"},{"key":"2026071609163920200_bib52","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1186\/s12964-026-02915-y","article-title":"Metabolic reprogramming of Th17\/Treg imbalance in autoimmune thyroid diseases","volume":"24","author":"Zhou","year":"2026","journal-title":"Cell Commun Signal"},{"key":"2026071609163920200_bib53","doi-asserted-by":"crossref","first-page":"8972572","DOI":"10.1155\/2018\/8972572","article-title":"Constitutive changes in circulating follicular helper T cells and their subsets in patients with Graves\u2019 disease","volume":"2018","author":"Liu","year":"2018","journal-title":"J Immunol Res"},{"key":"2026071609163920200_bib54","first-page":"4130","article-title":"B7.1 costimulatory molecule is expressed on thyroid follicular cells in Hashimoto\u2019s thyroiditis, but not in Graves\u2019 disease","volume":"83","author":"Battifora","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2026071609163920200_bib55","first-page":"4137","article-title":"Lack of B7-1\/BB1 and B7-2\/B70 expression on thyrocytes of patients with Graves\u2019 disease. Delivery of costimulatory signals from bystander professional antigen-presenting cells","volume":"81","author":"Matsuoka","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2026071609163920200_bib56","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1007\/s10875-012-9711-2","article-title":"Involvement of inducible costimulator ligand (ICOSL) expression in thyroid tissue in hyperthyroidism of Graves\u2019 disease patients","volume":"32","author":"Wang","year":"2012","journal-title":"J Clin Immunol"},{"key":"2026071609163920200_bib57","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1507\/endocrj.EJ15-0435","article-title":"Association of polymorphisms in the ICOS and ICOSL genes with the pathogenesis of autoimmune thyroid diseases","volume":"63","author":"Yoshie","year":"2016","journal-title":"Endocr J"},{"key":"2026071609163920200_bib58","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/10408363.2018.1522292","article-title":"Exploring the role of programmed cell death protein 1 and its ligand 1 in eye diseases","volume":"56","author":"Wang","year":"2019","journal-title":"Crit Rev Clin Lab Sci"},{"key":"2026071609163920200_bib59","article-title":"PD-L1 inhibits T cell-induced cytokines and Hyaluronan expression via the CD40-CD40L pathway in orbital fibroblasts from patients with thyroid associated ophthalmopathy","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"2026071609163920200_bib60","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nrendo.2013.56","article-title":"GWAS in autoimmune thyroid disease: redefining our understanding of pathogenesis","volume":"9","author":"Simmonds","year":"2013","journal-title":"Nat Rev Endocrinol"},{"key":"2026071609163920200_bib61","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/35057149","article-title":"A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms","volume":"409","author":"Sachidanandam","year":"2001","journal-title":"Nature"},{"key":"2026071609163920200_bib62","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1101\/gr.8.12.1229","article-title":"A DNA polymorphism discovery resource for research on human genetic variation","volume":"8","author":"Collins","year":"1998","journal-title":"Genome Res"},{"key":"2026071609163920200_bib63","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature01621","article-title":"Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease","volume":"423","author":"Ueda","year":"2003","journal-title":"Nature"},{"key":"2026071609163920200_bib64","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/08820139.2019.1688343","article-title":"Increases of CD80 and CD86 expression on peripheral blood cells and their gene polymorphisms in autoimmune thyroid disease","volume":"49","author":"Watanabe","year":"2020","journal-title":"Immunol Investig"},{"key":"2026071609163920200_bib65","doi-asserted-by":"crossref","first-page":"110614","DOI":"10.18632\/oncotarget.22702","article-title":"Association between rs3087243 and rs231775 polymorphism within the cytotoxic T-lymphocyte antigen 4 gene and Graves\u2019 disease: a case\/control study combined with meta-analyses","volume":"8","author":"Tu","year":"2017","journal-title":"Oncotarget"},{"key":"2026071609163920200_bib66","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.3390\/diagnostics13152517","article-title":"The C55A single nucleotide polymorphism in CTLA-4 gene, a new possible biomarker in thyroid autoimmune pathology such as Hashimoto\u2019s thyroiditis","volume":"13","author":"Chiorean","year":"2023","journal-title":"Diagnostics"},{"key":"2026071609163920200_bib67","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1210\/jc.2007-0147","article-title":"Cytotoxic T-lymphocyte associated antigen 4 gene polymorphisms and autoimmune thyroid disease: a meta-analysis","volume":"92","author":"Kavvoura","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2026071609163920200_bib68","doi-asserted-by":"crossref","first-page":"415","DOI":"10.5114\/aoms.2012.28593","article-title":"CTLA-4 gene polymorphisms and their influence on predisposition to autoimmune thyroid diseases (Graves\u2019 disease and Hashimoto\u2019s thyroiditis)","volume":"8","author":"Pastuszak-Lewandoska","year":"2012","journal-title":"Arch Med Sci"},{"key":"2026071609163920200_bib69","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/cen.14923","article-title":"Association of B7H3 and B7H4 gene polymorphisms and protein expression with the development and prognosis of autoimmune thyroid diseases","volume":"99","author":"Ozaki","year":"2023","journal-title":"Clin Endocrinol"},{"key":"2026071609163920200_bib70","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/747816","article-title":"Cytotoxic T lymphocyte-associated antigen 4 gene polymorphisms and autoimmune thyroid diseases: an updated systematic review and cumulative meta-analysis","volume":"2015","author":"Hou","year":"2015","journal-title":"Int J Endocrinol"},{"key":"2026071609163920200_bib71","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ophtha.2010.07.021","article-title":"The association between polymorphisms of B7 molecules (CD80 and CD86) and Graves\u2019 ophthalmopathy in a Taiwanese population","volume":"118","author":"Liao","year":"2011","journal-title":"Ophthalmology"},{"key":"2026071609163920200_bib72","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2114244118","article-title":"Therapeutic IGF-I receptor inhibition alters fibrocyte immune phenotype in thyroid-associated ophthalmopathy","volume":"118","author":"Fernando","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026071609163920200_bib73","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S2213-8587(25)00066-X","article-title":"Thyroid eye disease (Graves\u2019 orbitopathy): clinical presentation, epidemiology, pathogenesis, and management","volume":"13","author":"Wiersinga","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026071609163920200_bib74","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","article-title":"Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition","volume":"353","author":"Genovese","year":"2005","journal-title":"N Engl J Med"},{"key":"2026071609163920200_bib75","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1002\/art.40479","article-title":"Brief report: a randomized, double-blind, parallel-group, placebo-controlled, multiple-dose study to evaluate AMG 557 in patients with systemic lupus erythematosus and active lupus arthritis","volume":"70","author":"Cheng","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2026071609163920200_bib76","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/acr2.11487","article-title":"Safety and biological activity of Rozibafusp alfa, a bispecific inhibitor of inducible costimulator ligand and B cell activating factor, in patients with rheumatoid arthritis: results of a phase 1b, randomized, double-blind, placebo-controlled, multiple ascending dose study","volume":"4","author":"Abuqayyas","year":"2022","journal-title":"ACR Open Rheumatol"},{"key":"2026071609163920200_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113398","article-title":"Amelioration of experimental autoimmune encephalomyelitis by exogenous soluble PD-L1 is associated with restraining dendritic cell maturation and CCR7-mediated migration","volume":"143","author":"Mi","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"2026071609163920200_bib78","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-026-02583-z","article-title":"Targeting inflammatory microenvironments: overcoming therapy resistance and immunosuppression","volume":"25","author":"Zhou","year":"2026","journal-title":"Mol Cancer"},{"key":"2026071609163920200_bib79","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-024-01757-9","article-title":"NF-\u03baB in biology and targeted therapy: new insights and translational implications","volume":"9","author":"Guo","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"2026071609163920200_bib80","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.semcancer.2019.05.019","article-title":"Thyroid autoimmune disorders and cancer","volume":"64","author":"Ferrari","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"2026071609163920200_bib81","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3389\/fonc.2017.00053","article-title":"Association between Hashimoto\u2019s thyroiditis and thyroid cancer in 64,628 patients","volume":"7","author":"Resende de Paiva","year":"2017","journal-title":"Front Oncol"},{"key":"2026071609163920200_bib82","doi-asserted-by":"crossref","DOI":"10.1080\/08916934.2026.2639801","article-title":"Exploring the molecular mechanisms underlying the inflammation-cancer transformation in Hashimoto thyroiditis using single-cell transcriptomics","volume":"59","author":"Zou","year":"2026","journal-title":"Autoimmunity"},{"key":"2026071609163920200_bib83","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s12022-018-9540-9","article-title":"Papillary thyroid carcinoma emerging from hashimoto thyroiditis demonstrates increased PD-L1 expression, which persists with metastasis","volume":"29","author":"Lubin","year":"2018","journal-title":"Endocr Pathol"},{"key":"2026071609163920200_bib84","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.819236","article-title":"Clinical significance of the expression of Co-Stimulatory molecule B7-H3 in papillary thyroid carcinoma","volume":"10","author":"Zhao","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"2026071609163920200_bib85","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.7314\/APJCP.2013.14.5.3011","article-title":"B7-H4 expression is associated with cancer progression and predicts patient survival in human thyroid cancer","volume":"14","author":"Zhu","year":"2013","journal-title":"Asian Pac J Cancer Prev"},{"key":"2026071609163920200_bib86","article-title":"B7-H3\/CD276: an emerging cancer immunotherapy","volume":"12","author":"Zhou","year":"2021","journal-title":"Front Immunol"},{"key":"2026071609163920200_bib87","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.24811","article-title":"Evaluation of serum B7-H3 expression, ultrasound and clinical characteristics to predict the risk of cervical lymph node metastases in papillary thyroid carcinoma by nomogram","volume":"37","author":"Huang","year":"2023","journal-title":"J Clin Lab Anal"},{"key":"2026071609163920200_bib88","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.2147\/IJGM.S338564","article-title":"Human endogenous retrovirus-H long terminal repeat-associating protein 2 possesses prognostic significance and promotes progression of papillary thyroid cancer","volume":"15","author":"Niu","year":"2022","journal-title":"Int J Gen Med"},{"key":"2026071609163920200_bib89","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1530\/ERC-16-0421","article-title":"Comprehensive screening for PD-L1 expression in thyroid cancer","volume":"24","author":"Ahn","year":"2017","journal-title":"Endocr Relat Cancer"},{"key":"2026071609163920200_bib90","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3892\/ol.2021.12814","article-title":"PD-L1 expression and immune cells in anaplastic carcinoma and poorly differentiated carcinoma of the human thyroid gland: a retrospective study","volume":"22","author":"Cameselle-Garc\u00eda","year":"2021","journal-title":"Oncol Lett"},{"key":"2026071609163920200_bib91","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s12020-019-01865-5","article-title":"Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer","volume":"64","author":"Cantara","year":"2019","journal-title":"Endocrine"},{"key":"2026071609163920200_bib92","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1210\/jc.2016-3756","article-title":"Expression of PD-1 and PD-L1 in anaplastic thyroid cancer patients treated with multimodal therapy: results from a retrospective study","volume":"102","author":"Chintakuntlawar","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"2026071609163920200_bib93","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/his.13230","article-title":"CD70 and PD-L1 in anaplastic thyroid cancer \u2013 promising targets for immunotherapy","volume":"71","author":"Zwaenepoel","year":"2017","journal-title":"Histopathology"},{"key":"2026071609163920200_bib94","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s12253-014-9876-5","article-title":"Anaplastic thyroid cancer: outcome and the mutation\/expression profiles of potential targets","volume":"21","author":"Wu","year":"2015","journal-title":"Pathol Oncol Res"},{"key":"2026071609163920200_bib95","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.3390\/cancers16213632","article-title":"PD-L1 expression varies in thyroid cancer types and is associated with decreased progression free survival (PFS) in patients with anaplastic thyroid cancer","volume":"16","author":"Shobab","year":"2024","journal-title":"Cancers"},{"key":"2026071609163920200_bib96","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1089\/thy.2014.0134","article-title":"BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration","volume":"24","author":"Angell","year":"2014","journal-title":"Thyroid"},{"key":"2026071609163920200_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.107090","article-title":"Papillary thyroid carcinoma with a high tumor mutation burden has a poor prognosis","volume":"89","author":"Xie","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"2026071609163920200_bib98","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.674616","article-title":"Tumor mutation burden predicts relapse in papillary thyroid carcinoma with changes in genes and immune microenvironment","volume":"12","author":"Guo","year":"2021","journal-title":"Front Endocrinol"},{"key":"2026071609163920200_bib99","doi-asserted-by":"crossref","first-page":"32318","DOI":"10.18632\/oncotarget.8698","article-title":"Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants","volume":"7","author":"Chowdhury","year":"2016","journal-title":"Oncotarget"},{"key":"2026071609163920200_bib100","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s12022-018-9514-y","article-title":"PD-L1 and IDO1 are expressed in poorly differentiated thyroid carcinoma","volume":"29","author":"Rosenbaum","year":"2018","journal-title":"Endocr Pathol"},{"key":"2026071609163920200_bib101","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ejso.2018.10.060","article-title":"PD-1\/PD-L1 expressions in medullary thyroid carcinoma: clinicopathologic and prognostic analysis of Chinese population","volume":"45","author":"Bi","year":"2019","journal-title":"Eur J Surg Oncol"},{"key":"2026071609163920200_bib102","doi-asserted-by":"crossref","first-page":"L35","DOI":"10.1530\/ERC-17-0104","article-title":"Very low expression of PD-L1 in medullary thyroid carcinoma","volume":"24","author":"Bongiovanni","year":"2017","journal-title":"Endocr Relat Cancer"},{"key":"2026071609163920200_bib103","first-page":"106","article-title":"PD-L1 expression in medullary thyroid carcinoma and its association with clinicopathological findings","volume":"38","author":"Kemal","year":"2022","journal-title":"Turk Patoloji Derg"},{"key":"2026071609163920200_bib104","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1089\/thy.2019.0079","article-title":"Association between programmed death-ligand 1 expression and clinicopathological characteristics, structural recurrence, and biochemical recurrence\/persistent disease in medullary thyroid carcinoma","volume":"29","author":"Shi","year":"2019","journal-title":"Thyroid"},{"key":"2026071609163920200_bib105","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.929091","article-title":"What is the status of immunotherapy in thyroid neoplasms?","volume":"13","author":"Garcia-Alvarez","year":"2022","journal-title":"Front Endocrinol"},{"key":"2026071609163920200_bib106","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40618-023-02126-z","article-title":"Clinicopathological and prognostic significance of PD-L1 and TIM-3 expression in medullary thyroid carcinoma: a retrospective immunohistochemistry study","volume":"47","author":"Wusiman","year":"2024","journal-title":"J Endocrinol Investig"},{"key":"2026071609163920200_bib107","doi-asserted-by":"crossref","first-page":"e007530","DOI":"10.1136\/jitc-2023-007530","article-title":"New perspectives in cancer immunotherapy: targeting IL-6 cytokine family","volume":"11","author":"Soler","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026071609163920200_bib108","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1111\/cas.14752","article-title":"Interleukin 6 regulates the expression of programmed cell death ligand 1 in thyroid cancer","volume":"112","author":"Zhang","year":"2021","journal-title":"Cancer Sci"},{"key":"2026071609163920200_bib109","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13046-020-01818-1","article-title":"PD-1 blockade delays tumor growth by inhibiting an intrinsic SHP2\/Ras\/MAPK signalling in thyroid cancer cells","volume":"40","author":"Liotti","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"2026071609163920200_bib110","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/labinvest.2014.73","article-title":"VSIG4 expression on macrophages facilitates lung cancer development","volume":"94","author":"Liao","year":"2014","journal-title":"Lab Invest"},{"key":"2026071609163920200_bib111","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13046-025-03303-z","article-title":"VSIG4(+) tumor-associated macrophages mediate neutrophil infiltration and impair antigen-specific immunity in aggressive cancers through epigenetic regulation of SPP1","volume":"44","author":"Pan","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"2026071609163920200_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2026.168303","article-title":"HN1\/CEBPB\/CCL2 signaling shapes VSIG4(+) tumor-associated macrophages in anaplastic thyroid carcinoma","volume":"1872","author":"Fang","year":"2026","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"2026071609163920200_bib113","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.coi.2017.01.001","article-title":"Immune checkpoint receptors in cancer: redundant by design?","volume":"45","author":"Li","year":"2017","journal-title":"Curr Opin Immunol"},{"key":"2026071609163920200_bib114","doi-asserted-by":"crossref","first-page":"6682","DOI":"10.1073\/pnas.1420370112","article-title":"Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses","volume":"112","author":"Liu","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026071609163920200_bib115","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.982026","article-title":"Harnessing the immune system by targeting immune checkpoints: providing new hope for oncotherapy","volume":"13","author":"Yu","year":"2022","journal-title":"Front Immunol"},{"key":"2026071609163920200_bib116","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fonc.2018.00086","article-title":"Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations","volume":"8","author":"Seidel","year":"2018","journal-title":"Front Oncol"},{"key":"2026071609163920200_bib117","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1001\/jamaoncol.2024.4019","article-title":"Dual immune checkpoint inhibition in patients with aggressive thyroid carcinoma: a phase 2 nonrandomized clinical trial","volume":"10","author":"Sehgal","year":"2024","journal-title":"JAMA Oncol"},{"key":"2026071609163920200_bib118","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.1038\/s41467-026-71155-y","article-title":"Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial","volume":"17","author":"Capdevila","year":"2026","journal-title":"Nat Commun"},{"key":"2026071609163920200_bib119","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"2026071609163920200_bib120","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s40364-024-00665-y","article-title":"Soluble PD-L1 as a novel biomarker predicts poor outcomes and disease progression in de novo myelodysplastic syndromes","volume":"12","author":"Yang","year":"2024","journal-title":"Biomark Res"},{"key":"2026071609163920200_bib121","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"2026071609163920200_bib122","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/S1470-2045(15)00307-1","article-title":"PD-L1 expression as a potential predictive biomarker","volume":"16","author":"Fusi","year":"2015","journal-title":"Lancet Oncol"},{"key":"2026071609163920200_bib123","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/s12943-025-02400-z","article-title":"Overcoming resistance to anti-PD-L1 immunotherapy: mechanisms, combination strategies, and future directions","volume":"24","author":"Mandal","year":"2025","journal-title":"Mol Cancer"},{"key":"2026071609163920200_bib124","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1200\/JCO.19.02727","article-title":"PD-1 blockade in anaplastic thyroid carcinoma","volume":"38","author":"Capdevila","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026071609163920200_bib125","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/cncr.34657","article-title":"Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study","volume":"129","author":"Oh","year":"2023","journal-title":"Cancer"},{"key":"2026071609163920200_bib126","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"key":"2026071609163920200_bib127","doi-asserted-by":"crossref","first-page":"e010928","DOI":"10.1136\/jitc-2024-010928","article-title":"Society for immunotherapy of cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols","volume":"13","author":"Cottrell","year":"2025","journal-title":"J Immunother Cancer"},{"key":"2026071609163920200_bib128","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1089\/thy.2023.0573","article-title":"Checkpoint inhibition in addition to dabrafenib\/trametinib for BRAF(V600E)-mutated anaplastic thyroid carcinoma","volume":"34","author":"Hamidi","year":"2024","journal-title":"Thyroid"},{"key":"2026071609163920200_bib129","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/CCO.0000000000000727","article-title":"Emerging systemic antitarget treatment for differentiated thyroid carcinoma","volume":"33","author":"Bast\u00e9","year":"2021","journal-title":"Curr Opin Oncol"},{"key":"2026071609163920200_bib130","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12885-019-5380-3","article-title":"Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer","volume":"19","author":"Mehnert","year":"2019","journal-title":"BMC Cancer"},{"key":"2026071609163920200_bib131","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1001\/jamaoncol.2024.4729","article-title":"Anti-programmed death ligand 1 plus targeted therapy in anaplastic thyroid carcinoma: a nonrandomized clinical trial","volume":"10","author":"Cabanillas","year":"2024","journal-title":"JAMA Oncol"},{"key":"2026071609163920200_bib132","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1089\/thy.2019.0086","article-title":"A phase 2 study of pembrolizumab combined with chemoradiotherapy as initial treatment for anaplastic thyroid cancer","volume":"29","author":"Chintakuntlawar","year":"2019","journal-title":"Thyroid"},{"key":"2026071609163920200_bib133","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1089\/thy.2021.0371","article-title":"Lenvatinib plus anti-PD-1 combination therapy for advanced cancers: defining mechanisms of resistance in an inducible transgenic model of thyroid cancer","volume":"32","author":"Bertol","year":"2022","journal-title":"Thyroid"},{"key":"2026071609163920200_bib134","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/s41416-018-0296-2","article-title":"Combinations of BRAF inhibitor and anti-PD-1\/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer","volume":"119","author":"Gunda","year":"2018","journal-title":"Br J Cancer"},{"key":"2026071609163920200_bib135","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920937612","article-title":"Efficacy of PD-1\/PD-L1 blockade monotherapy in clinical trials","volume":"12","author":"Zhao","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"2026071609163920200_bib136","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf348","article-title":"Pembrolizumab in recurrent or metastatic medullary thyroid cancer","volume":"31","author":"Del Rivero","year":"2025","journal-title":"Oncologist"},{"key":"2026071609163920200_bib137","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.173712","article-title":"A distinct tumor microenvironment makes anaplastic thyroid cancer more lethal but immunotherapy sensitive than papillary thyroid cancer","volume":"9","author":"Han","year":"2024","journal-title":"JCI Insight"},{"key":"2026071609163920200_bib138","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1038\/s41467-025-58910-3","article-title":"Integrative proteogenomic characterization reveals therapeutic targets in poorly differentiated and anaplastic thyroid cancers","volume":"16","author":"Pan","year":"2025","journal-title":"Nat Commun"},{"key":"2026071609163920200_bib139","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1158\/2326-6066.CIR-21-0407","article-title":"B7-H3 suppresses antitumor immunity via the CCL2-CCR2-M2 macrophage axis and contributes to ovarian cancer progression","volume":"10","author":"Miyamoto","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"2026071609163920200_bib140","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1038\/s41467-026-68525-x","article-title":"Palmitic acid-triggered B7H3 palmitoylation promotes immune escape","volume":"17","author":"Rao","year":"2026","journal-title":"Nat Commun"},{"key":"2026071609163920200_bib141","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1158\/2326-6066.CIR-22-0116","article-title":"VISTA targeting of T-cell quiescence and Myeloid suppression overcomes adaptive resistance","volume":"11","author":"Schaafsma","year":"2023","journal-title":"Cancer Immunol Res"},{"key":"2026071609163920200_bib142","article-title":"CAR-T cell therapy in advanced thyroid cancer: from basic to clinical","volume":"15","author":"Sun","year":"2024","journal-title":"Front Immunol"},{"key":"2026071609163920200_bib143","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/s41591-024-03451-3","article-title":"Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial","volume":"31","author":"Vitanza","year":"2025","journal-title":"Nat Med"},{"key":"2026071609163920200_bib144","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1158\/1078-0432.CCR-23-1079","article-title":"A B7-H4-Targeting antibody-drug conjugate shows antitumor activity in PARPi and platinum-resistant cancers with B7-H4 expression","volume":"30","author":"Gitto","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026071609163920200_bib145","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1158\/2326-6066.CIR-20-0949","article-title":"CD86(+) antigen-presenting B cells are increased in cancer, localize in tertiary lymphoid structures, and induce specific T-cell responses","volume":"9","author":"Wennhold","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"2026071609163920200_bib146","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2444697","article-title":"From PD-1\/PD-L1 to tertiary lymphoid structures: paving the way for precision immunotherapy in cholangiocarcinoma treatment","volume":"21","author":"Huang","year":"2025","journal-title":"Hum Vaccin Immunother"},{"key":"2026071609163920200_bib147","doi-asserted-by":"crossref","first-page":"88","DOI":"10.2174\/0113892029278082240118053857","article-title":"Tertiary lymphoid structures gene signature predicts prognosis and immune infiltration analysis in head and neck squamous cell carcinoma","volume":"25","author":"Xing","year":"2024","journal-title":"Curr Genomics"},{"key":"2026071609163920200_bib148","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s12105-025-01815-w","article-title":"Spatial transcriptome analysis of B7-H4 in head and neck squamous cell carcinoma: a novel therapeutic target for anti-immune checkpoint inhibitors","volume":"19","author":"Noda","year":"2025","journal-title":"Head Neck Pathol"},{"key":"2026071609163920200_bib149","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1158\/2326-6066.CIR-24-0071","article-title":"Spatially resolved whole-transcriptomic and proteomic profiling of lung cancer and its immune microenvironment according to PD-L1 expression","volume":"12","author":"Koh","year":"2024","journal-title":"Cancer Immunol Res"},{"key":"2026071609163920200_bib150","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70172","article-title":"Single-cell RNA-sequencing and spatial transcriptomic analysis reveal a distinct population of APOE(\u2212) cells yielding pathological lymph node metastasis in papillary thyroid cancer","volume":"15","author":"Xiao","year":"2025","journal-title":"Clin Transl Med"},{"key":"2026071609163920200_bib151","doi-asserted-by":"crossref","first-page":"5895","DOI":"10.1038\/s41467-024-50192-5","article-title":"Unraveling the molecular architecture of autoimmune thyroid diseases at spatial resolution","volume":"15","author":"Mart\u00ednez-Hern\u00e1ndez","year":"2024","journal-title":"Nat Commun"},{"key":"2026071609163920200_bib152","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.191990","article-title":"An integrated single-cell and spatial transcriptomic atlas of thyroid cancer progression identifies prognostic fibroblast subpopulations","volume":"11","author":"Loberg","year":"2026","journal-title":"JCI Insight"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/aop\/ERC-25-0435\/ERC-25-0435.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/aop\/ERC-25-0435\/ERC-25-0435.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-25-0435\/519686\/erc-25-0435.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-25-0435\/519686\/erc-25-0435.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T13:16:59Z","timestamp":1784207819000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article\/33\/7\/e250435\/77514\/The-role-of-the-B7-family-in-autoimmune-thyroid"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":152,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1530\/erc-25-0435","relation":{},"ISSN":["1351-0088","1479-6821"],"issn-type":[{"value":"1351-0088","type":"print"},{"value":"1479-6821","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"article-number":"e250435"}}